Oxford University
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Oxford University
Jun 30, 2024, 08:07 |
Societies
9 Posts You Should Not Miss From Day 3 of ESMOGI24!
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…
Jun 30, 2024, 02:46 |
Blog
Dana-Farber Cancer Institute - William Kaelin Jr. was recognized with the Stanley P. Reimann Honor Award
Dana-Farber Cancer Institute shared on LinkedIn: "William Kaelin Jr., MD, physician, scientist, and Nobel laureate, was recognized…
Jun 29, 2024, 10:24 |
Societies
Magnus Nilsson discusses when and why we should operate in esophageal cancer
Lizzy Smyth, Consultant Medical Oncologist in upper GI oncology at Oxford University, shared on X:…
Jun 27, 2024, 08:56 |
Societies
Teresa Macarulla kicks it off at ESMOGI24
Lizzy Smyth, Consultant Medical Oncologist in upper GI oncology at Oxford University, shared on X:…
May 22, 2024, 11:01 |
Blog
Josh Atkins: Identifying Proteomic Risk Factors
Josh Atkins, Senior Cancer Genomic Epidemiologist at the Nuffield Department of Population Health of Oxford…
Mar 30, 2024, 10:44 |
Blog
Jennifer DuBois: Though she was the first woman on the Oxford University faculty to be given maternity leave, there was more to Dorothy Crowfoot Hodgkin's career than simply combining parenthood and science
Nov 15, 2023, 20:47 |
Blog
Mariam Hibah Khayata: I am grateful to share that I have been awarded the Rhodes Scholarship
Mariam Hibah Khayata, Global Education Coordinator at St. Jude Children's Research Hospital - ALSAC, made…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube